Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3002 Multiple Dosing in Healthy Participants and Patients With Asthma
NCT06947408Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3002 in asthma (9 arms), sponsored by Innovent Biologics. Primary endpoint: Incidence of sudden adverse events at 16 weeks. Started May 2025; status: completed.
02
Drugs
IBI3002
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06947408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947408.